DGCR6L

Summary

DGCR6L (DiGeorge syndrome critical region gene 6 like, HGNC:18551) is a protein-coding gene on chromosome 22q11.21, encoding Protein DGCR6L (Q9BY27). May play a role in neural crest cell migration into the third and fourth pharyngeal pouches.

This gene, the result of a duplication at this locus, is one of two functional genes encoding nearly identical proteins that have similar expression patterns. The product of this gene is a protein that shares homology with the Drosophila gonadal protein, expressed in gonadal tissues and germ cells, and with the human laminin gamma-1 chain that functions in cell attachment and migration. This gene is located in a region of chromosome 22 implicated in the DiGeorge syndrome, one facet of a broader collection of anomalies referred to as the CATCH 22 syndrome.

Source: NCBI Gene 85359 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 47 total — 1 pathogenic
• MANE Select transcript: NM_033257

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18551
Approved symbol	DGCR6L
Name	DiGeorge syndrome critical region gene 6 like
Location	22q11.21
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10666
Ensembl gene	ENSG00000128185
Ensembl biotype	protein_coding
OMIM	609459
Entrez	85359

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 nonsense_mediated_decay

ENST00000248879, ENST00000405465, ENST00000443409, ENST00000875445, ENST00000911281, ENST00000911282, ENST00000911283, ENST00000911284, ENST00000911285, ENST00000911286

RefSeq mRNA: 1 — MANE Select: NM_033257 NM_033257

CCDS: CCDS13778

Canonical transcript exons

ENST00000248879 — 5 exons

Exon	Start	End
ENSE00001599785	20316119	20316219
ENSE00001731392	20319639	20319799
ENSE00001855855	20314238	20314824
ENSE00003674176	20315336	20315476
ENSE00003889878	20319879	20320060

Expression profiles

Bgee: expression breadth ubiquitous, 142 present calls, max score 97.97.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.4948 / max 87.8434, expressed in 1799 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
193191	17.4948	1799

Top tissues by expression

142 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	97.97	gold quality
left testis	UBERON:0004533	97.79	gold quality
testis	UBERON:0000473	97.30	gold quality
right lobe of liver	UBERON:0001114	96.82	gold quality
apex of heart	UBERON:0002098	96.01	gold quality
amygdala	UBERON:0001876	95.69	gold quality
temporal lobe	UBERON:0001871	95.66	gold quality
putamen	UBERON:0001874	95.63	gold quality
nucleus accumbens	UBERON:0001882	95.39	gold quality
anterior cingulate cortex	UBERON:0009835	95.20	gold quality
caudate nucleus	UBERON:0001873	95.13	gold quality
Ammon’s horn	UBERON:0001954	95.13	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.12	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.80	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.73	gold quality
right frontal lobe	UBERON:0002810	94.67	gold quality
hypothalamus	UBERON:0001898	94.64	gold quality
cerebral cortex	UBERON:0000956	94.53	gold quality
substantia nigra	UBERON:0002038	94.51	gold quality
liver	UBERON:0002107	94.39	gold quality
prefrontal cortex	UBERON:0000451	94.28	gold quality
frontal cortex	UBERON:0001870	94.28	gold quality
gastrocnemius	UBERON:0001388	94.27	gold quality
muscle of leg	UBERON:0001383	93.84	gold quality
heart left ventricle	UBERON:0002084	93.80	gold quality
brain	UBERON:0000955	93.66	gold quality
adult mammalian kidney	UBERON:0000082	93.57	gold quality
primary visual cortex	UBERON:0002436	93.50	gold quality
spinal cord	UBERON:0002240	93.44	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.44	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-112	no	3.61
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

8 targeting DGCR6L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-3926	98.95	69.26	1438
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-296-5P	97.61	64.02	851
HSA-MIR-4640-5P	97.42	66.33	1543
HSA-MIR-6508-3P	96.73	65.48	576
HSA-MIR-3974	96.56	66.22	928
HSA-MIR-3677-5P	93.16	64.62	393

Literature-anchored findings (GeneRIF, showing 2)

• DGCR6L, a novel PAK4 interacting protein, regulated PAK4-mediated migration of human gastric cancer cells via LIMK1. (PMID:19778628)
• Further studies are now needed to test the usefulness of DGCR6 and DGCR6L expression and alterations in the epigenome at these loci in predicting childhood anxiety and associated adult-onset pathologies in 22q11DS subjects. (PMID:22832905)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dgcr6	ENSDARG00000005500
mus_musculus	Dgcr6	ENSMUSG00000003531
rattus_norvegicus	Dgcr6	ENSRNOG00000001880
drosophila_melanogaster	gdl	FBGN0001099

Paralogs (2): DGCR6 (ENSG00000183628), (ENSG00000278817)

Protein

Protein identifiers

Protein DGCR6L — Q9BY27 (reviewed: Q9BY27)

Alternative names: DiGeorge syndrome critical region 6-like protein

All UniProt accessions (3): Q9BY27, B5MCQ4, F8WCX1

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in neural crest cell migration into the third and fourth pharyngeal pouches.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed in fetal and adult tissues. Highest expression in liver, heart and skeletal muscle. Lower levels in pancreas and placenta. Weak expression in brain.

Similarity. Belongs to the gonadal family.

RefSeq proteins (1): NP_150282* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010849	Gonadal	Family

Pfam: PF07324

UniProt features (6 total): sequence variant 2, sequence conflict 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BY27-F1	87.10	0.72

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 33 (showing top): JIANG_VHL_TARGETS, JIANG_HYPOXIA_VIA_VHL, KRAS.600.LUNG.BREAST_UP.V1_DN, GUCY1B1_TARGET_GENES, MAFG_TARGET_GENES, NFE2L1_TARGET_GENES, TASOR_TARGET_GENES, SAFB2_TARGET_GENES, WP_22Q112_COPY_NUMBER_VARIATION_SYNDROME, DESCARTES_MAIN_FETAL_AFP_ALB_POSITIVE_CELLS, DESCARTES_FETAL_HEART_ERYTHROBLASTS, DESCARTES_FETAL_SPLEEN_AFP_ALB_POSITIVE_CELLS, SETBP1_TARGET_GENES, LOPEZ_MBD_TARGETS, TRAVAGLINI_LUNG_PROXIMAL_CILIATED_CELL

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

560 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DGCR6L	PRODH	O43272	884
DGCR6L	ZNF74	Q16587	841
DGCR6L	DGCR2	P98153	831
DGCR6L	PRODH	O43272	796
DGCR6L	HIRA	P54198	756
DGCR6L	SERPIND1	P05546	716
DGCR6L	TBX1	O43435	705
DGCR6L	GNB1L	Q9BYB4	684
DGCR6L	PAK4	O96013	665
DGCR6L	COMT	P21964	612
DGCR6L	GSC2	O15499	596
DGCR6L	ZDHHC8	Q9ULC8	581
DGCR6L	UFD1	Q92890	571
DGCR6L	MRPL40	Q9NQ50	537
DGCR6L	ZNF490	Q9ULM2	490

IntAct

87 interactions, top by confidence:

A	B	Type	Score
DEUP1	DGCR6L	psi-mi:“MI:0915”(physical association)	0.720
MID2	DGCR6L	psi-mi:“MI:0915”(physical association)	0.720
DGCR6L	DEUP1	psi-mi:“MI:0915”(physical association)	0.720
DGCR6L	MID2	psi-mi:“MI:0915”(physical association)	0.720
DGCR6L	INIP	psi-mi:“MI:0915”(physical association)	0.600
INIP	DGCR6L	psi-mi:“MI:0915”(physical association)	0.600
KRT31	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560
DGCR6L	LZTS2	psi-mi:“MI:0915”(physical association)	0.560
DGCR6L	RIMBP3	psi-mi:“MI:0915”(physical association)	0.560
LZTS2	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560
DGCR6L	KRT31	psi-mi:“MI:0915”(physical association)	0.560
DGCR6L	ZNF620	psi-mi:“MI:0915”(physical association)	0.560
PPP1R13B	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560
NAB2	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560
GATA1	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560
SPTA1	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560
ADAMTSL4	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560
NECAB2	DGCR6L	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (36): DGCR6L (Two-hybrid), DGCR6L (Two-hybrid), DGCR6L (Two-hybrid), RIMBP3 (Two-hybrid), CCDC67 (Two-hybrid), DGCR6L (Two-hybrid), DGCR6L (Two-hybrid), KCNRG (Two-hybrid), DGCR6L (Two-hybrid), DGCR6L (Two-hybrid), DGCR6L (Two-hybrid), DGCR6L (Two-hybrid), DGCR6L (Two-hybrid), PAK4 (Reconstituted Complex), DGCR6L (Reconstituted Complex)

ESM2 similar proteins: A1IGU3, A1IGU4, A1IGU5, A5D8V7, A5PK16, A6QP29, A7E3N7, A8K8P3, A9CB34, B0KWR6, B5DFA1, D3ZI76, G3HQ82, O73770, P0C7M6, P41002, Q14129, Q14DK4, Q15051, Q3SYS7, Q3UK37, Q3UZY0, Q5SNV9, Q5SXM2, Q60953, Q60I26, Q60I27, Q69ZT1, Q6NUI2, Q8BP00, Q8BP86, Q8C1F5, Q8C2K1, Q8CJ00, Q8IV45, Q8NCU4, Q8NE28, Q8NEE8, Q8TE82, Q95KD7

Diamond homologs: O35347, O73770, P22468, Q14129, Q9BY27

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	34
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
666443	GRCh37/hg19 22q11.21(chr22:18661724-21505417)x1	Pathogenic

SpliceAI

860 predictions. Top by Δscore:

Variant	Effect	Δscore
22:20315332:TGACC:T	donor_loss	1.0000
22:20315333:GACCT:G	donor_loss	1.0000
22:20315334:A:AC	donor_gain	1.0000
22:20315335:C:CC	donor_gain	1.0000
22:20315473:CGGC:C	acceptor_gain	1.0000
22:20315474:GGC:G	acceptor_gain	1.0000
22:20315475:GC:G	acceptor_gain	1.0000
22:20315475:GCCT:G	acceptor_loss	1.0000
22:20315476:CC:C	acceptor_gain	1.0000
22:20315477:C:A	acceptor_loss	1.0000
22:20315477:C:CC	acceptor_gain	1.0000
22:20315481:C:CT	acceptor_gain	1.0000
22:20315481:C:T	acceptor_gain	1.0000
22:20315482:A:C	acceptor_gain	1.0000
22:20315489:C:CT	acceptor_gain	1.0000
22:20315489:C:T	acceptor_gain	1.0000
22:20315490:A:T	acceptor_gain	1.0000
22:20315494:C:CT	acceptor_gain	1.0000
22:20315496:C:CT	acceptor_gain	1.0000
22:20316217:GCA:G	acceptor_gain	1.0000
22:20316218:CA:C	acceptor_gain	1.0000
22:20316218:CAC:C	acceptor_gain	1.0000
22:20316220:C:CC	acceptor_gain	1.0000
22:20319874:CGTA:C	donor_loss	1.0000
22:20319875:GTACC:G	donor_loss	1.0000
22:20319876:TA:T	donor_loss	1.0000
22:20319877:A:AT	donor_loss	1.0000
22:20315334:AC:A	donor_gain	0.9900
22:20315335:CC:C	donor_gain	0.9900
22:20315472:ACGGC:A	acceptor_gain	0.9900

AlphaMissense

1404 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:20315357:G:C	F164L	0.996
22:20315357:G:T	F164L	0.996
22:20315359:A:G	F164L	0.996
22:20315390:C:A	Q153H	0.996
22:20315390:C:G	Q153H	0.996
22:20319710:A:G	L67P	0.995
22:20315358:A:G	F164S	0.994
22:20319692:A:G	L73P	0.994
22:20319722:A:C	I63S	0.994
22:20319755:G:T	A52D	0.994
22:20315382:A:G	L156P	0.993
22:20319697:C:A	Q71H	0.992
22:20319697:C:G	Q71H	0.992
22:20319758:A:G	L51P	0.992
22:20315415:A:G	L145P	0.991
22:20319665:C:G	R82P	0.991
22:20314793:A:G	L182P	0.990
22:20315393:C:A	Q152H	0.990
22:20315393:C:G	Q152H	0.990
22:20315382:A:T	L156Q	0.989
22:20319677:A:G	L78P	0.989
22:20319685:T:A	E75D	0.989
22:20319685:T:G	E75D	0.989
22:20319722:A:T	I63N	0.989
22:20319746:A:T	L55H	0.989
22:20314802:A:G	L179P	0.988
22:20315349:G:A	T167I	0.988
22:20319722:A:G	I63T	0.988
22:20319746:A:G	L55P	0.988
22:20319701:A:G	I70T	0.986

dbSNP variants (sampled 300 via entrez): RS1000069961 (22:20315902 C>T), RS1000111803 (22:20316787 A>G), RS1001668014 (22:20318454 T>C), RS1001782404 (22:20318024 C>T), RS1003682701 (22:20320934 TG>T), RS1003714034 (22:20320770 C>T), RS1004050868 (22:20321966 G>A,T), RS1005932348 (22:20317927 G>A), RS1007245094 (22:20314492 C>T), RS1007519424 (22:20320475 G>A), RS1007818623 (22:20321773 T>G), RS1007852966 (22:20321582 G>T), RS1007944915 (22:20320719 G>C,T), RS1008503636 (22:20315950 G>A,T), RS1008887364 (22:20316155 C>T)

Disease associations

OMIM: gene MIM:609459 | disease phenotypes: MIM:188400, MIM:192430

GenCC curated gene-disease

Mondo (4): prostate cancer (MONDO:0008315), primary ovarian failure (MONDO:0005387), DiGeorge syndrome (MONDO:0008564), velocardiofacial syndrome (MONDO:0008644)

Orphanet (3): Familial prostate cancer (Orphanet:1331), 22q11.2 deletion syndrome (Orphanet:567), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D004062	DiGeorge Syndrome	C05.660.207.103.500; C14.240.400.021.500; C14.280.400.044.500; C15.604.451.249.500; C16.131.077.019.500; C16.131.240.400.021.500; C16.131.260.019.500; C16.131.482.249.500; C16.131.621.207.103.500; C16.320.180.019.500; C19.642.482.500.500
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Cisplatin	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
bisphenol A	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	affects expression	1
Indomethacin	increases expression, affects cotreatment	1
Smoke	decreases expression	1
Thiram	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	decreases expression	1
Vitamin K 3	affects expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer